Novo Nordisk (NVO) said Wednesday its US operations will no longer take part in a global initiative on gender representation because of "evolving legal requirements."
The company said that worldwide, it continues to work to achieve representation of at least 45% for each gender by the end of this year.
"We remain committed to non-discrimination and innovation through diverse perspectives, always in compliance with local regulations," the Danish drugmaker said in its Q1 earnings release.
Price: 68.68, Change: +2.39, Percent Change: +3.61
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。